Treatment of Behçet's Disease with Recurrent Mucocutaneous Lesions
Behçet's syndrome can follow a relapsing course with recurrent lesions affecting the mucous membranes and skin. In patients with this pattern of involvement, a structured treatment approach is required to reduce flare frequency and lesion burden.
Clinical Scenario
This protocol addresses Behçet's syndrome with recurrent mucocutaneous lesions — including oral ulcers, genital ulcers, erythema nodosum, and nodular lesions. Patients presenting with this mucocutaneous pattern represent a defined sub-population for whom a stepwise treatment strategy is recommended.
Treatment Approach
For selected patients in whom initial management is insufficient, systemic agents including certain immunomodulatory and biologic therapies are considered. The full protocol specifies the selection criteria, agent sequencing, and clinical decision points — access the complete regimen below.
References
DOI: 10.1136/annrheumdis-2018-213225
- Considering the safety and good tolerability of colchicine, the group agreed that it should be tried first in patients who have only mucocutaneous involvement.
- Drugs such as azathioprine, thalidomide, interferon-alpha, tumour necrosis factor-alpha inhibitors or apremilast should be considered in selected cases.
View source ↗